

RECEIVED

OCT 07 2002
TECH CENTER 1600/2800FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.417C1

APPLICATION NO.

09/960,264

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

Ronald Berenson et al.

FILING DATE

September 20, 2001

GROUP ART UNIT

1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
WJL	AA	5,190,878	03/02/93	Wilhelm	435	285	
	AB	5,858,358	01/12/99	June et al.	424	130.1	
	AC	5,888,807	03/30/99	Palsson et al.	435	293.2	
	AD	5,985,653	11/16/99	Armstrong et al.	435	303.1	
	AE	6,096,532	08/01/00	Armstrong et al.	435	286.5	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

WJL	AG	Bretscher, P., "The two-signal model of lymphocyte activation twenty-one years later," <i>Immunology Today</i> 13(2): 74-76, 1992.
	AH	Garland et al., "The use of Teflon cell culture bags to expand functionally active CD8 ⁺ cytotoxic T lymphocytes," <i>Journal of Immunological Methods</i> 227: 53-63, 1999.
	AI	Haanen et al., "Selective Expansion of Cross-reactive CD8 ⁺ Memory T Cells by Viral Variants," <i>J. Exp. Med.</i> 190(9): 1319-1328, November 1, 1999.
	AJ	Iezzi et al., "The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells," <i>Immunity</i> 8: 89-95, January 1998.
	AK	June et al., "The B7 and CD28 receptor families," <i>Immunology Today</i> 15(7): 321-331, 1994.
	AL	Kato et al., "Gene Transfer of CD40-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells," <i>J. Clin. Invest.</i> 101(5): 1133-1141, March 1998.
	AM	Krawczyk et al., "Cbl-b Is a Negative Regulator of Receptor Clustering and Raft Aggregation in T Cells," <i>Immunity</i> 13: 463-473, October 2000.
	AN	Liebowitz et al., "Costimulatory approaches to adoptive immunotherapy," <i>Current Opinion in Oncology</i> 10: 533-541, 1998.


EXAMINER

LANIKROD

DATE CONSIDERED

10/27/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

980034.417C1

APPLICATION NO.

09/960,264

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT


Ronald Berenson et al.

FILING DATE

September 20, 2001

GROUP ART UNIT

1615



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						

TECH CENTER 1600/2900

OCT 07 2002

RECEIVED

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BH					
	BI					
	BJ					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BL	BK	Ranheim and Kipps, "Activated T Cells Induce Expression of B7/BB1 on Normal or Leukemic B Cells through a CD40-dependent Signal," <i>J. Exp. Med.</i> 177: 925-935, April 1993.
↓	BL	Ten Berge et al., "Selective Expansion of a Peripheral Blood CD8 ⁺ Memory T Cell Subset Expressing Both Granzyme B and L-Selectin During Primary Viral Infection in Renal Allograft Recipients," <i>Transplantation Proceedings</i> 30: 3975-3977, 1998.
	BM	
	BN	
	BO	

EXAMINER

LANKFORD

DATE CONSIDERED

6/27/3

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BL	AA	5,735,279	04/07/98	Klaveness et al.	128	654	
	AB	5,962,319	10/05/99	Ogawa et al.	435	325	
	AC	6,352,694	03/05/02	June et al.	424	93.71	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
W	AD	WO 97/01304	01/16/97	WIPO	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BL	AE	Bonyhadi, M. et al., "Xcellerate: An Autologous T Cell Immunotherapy Approach for Treating B-Cell Lymphocytic Leukemia (B-CLL)," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 1, ABSTRACT # 3616.
	AF	Creson, J. et al., "The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro," <i>Journal Of Virology</i> , 73(11):9337-9347, November 1999.
	AG	Hami, L. et al., "Xcellerate™: A Platform Process for the GMP Manufacture of Activated T Cells for the Treatment of Patients with Cancer and Immune Dysfunction," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 1, abstract # 3630.
	AH	Kalamasz, D. et al., "Storage Shipment of Freshly Harvested or Cryopreserved Xcellerate™ Activated T Cells for Clinical Applications," in <i>Proceedings of the 42nd Annual Meeting of the American Society of Hematology</i> , San Francisco, December 1-5, 2000, vol. 96, no. 11, part 2, abstract # 5113.
	AI	Larsson, S. et al., "Productive Cytomegalovirus (CMV) Infection Exclusively in CD13-Positive Peripheral Blood Mononuclear Cells from CMV-Infected Individuals," <i>Transplantation</i> , 65(3):411-415, February 15, 1998.
	AJ	Polanski, M. et al., "Xcellerate(: A Closed, Scalable Process for the GMP Manufacture of Stable Activated T Cells," in <i>Proceedings of the 15th Annual Scientific Meeting of the Society for Biological Therapy</i> , Seattle, October 26-29, 2000, and <i>Journal of Immunotherapy</i> , (23)5:599, September 2000.


EXAMINER

LANKSOED

DATE CONSIDERED

6/27/03

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
980034.417C1APPLICATION NO.
09/960,264INFORMATION ENCLOSURE STATEMENT
(Include additional sheets if necessary)

APPLICANTS

Roanld Berenson et al.

FILING DATE

September 20, 2001

GROUP ART UNIT

1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>ML</i>	AA	5,837,477	11/17/98	Germain et al.	435	7.24	
<i>d</i>	AB	5,942,607	08/24/99	Freeman et al.	536	23.5	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP		
	AQ		
	AR		

EXAMINER

LANKER

DATE CONSIDERED

6/27/3

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).